• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
75,415.35 231.99
( 0.31%)
Global Indices
Nasdaq
50,600.73 294.06
(0.58%)
Dow Jones
7,493.73 27.01
(0.36%)
Hang Seng
63,328.42 1,644.28
(2.67%)
Nikkei 225
10,474.02 30.55
(0.29%)
Forex
USD-INR
96.29 -0.42
(-0.43%)
EUR-INR
111.82 -0.44
(-0.39%)
GBP-INR
129.28 -0.40
(-0.31%)
JPY-INR
0.61 0.00
(-0.48%)

EQUITY - MARKET SCREENER

BSE Bharat 22 Index
Industry :  Stock Exchanges
BSE Code
ISIN Demat
Book Value()
1016
N.A
0
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
13.75
4973425.73
EPS(TTM)
Face Value()
Div & Yield %
0
100
2.45
 

bodal chemicals ltd
Astrazeneca Pharma India gets CDSCO approval for Acalabrutinib tablets
Apr 13,2026
Through this approval, Acalabrutinib tablets 100 mg in combination with venetoclax with or without obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) /small lymphocytic lymphoma (SLL).

This regulatory clearance paves the way for the commercial launch and availability of Calquence in the Indian market.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company’s standalone net profit declined 42.3% to Rs 31.55 crore despite 38.9% increase in net sales to Rs 615.57 crore in Q3 FY26 over Q3 FY25.

The counter advanced 1.45% to end at Rs 8,291.50 on Friday, 10 April 2026.